Compare EPRT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | PTGX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.4B |
| IPO Year | 2018 | 2016 |
| Metric | EPRT | PTGX |
|---|---|---|
| Price | $30.14 | $97.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $36.79 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.3M | 480.8K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ 11.30 | N/A |
| EPS | ★ 0.28 | 0.05 |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $17.12 | $874.25 |
| Revenue Next Year | $16.27 | N/A |
| P/E Ratio | ★ $108.11 | $1,947.60 |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $28.95 | $49.86 |
| 52 Week High | $34.73 | $107.84 |
| Indicator | EPRT | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 46.14 |
| Support Level | $29.24 | $96.36 |
| Resistance Level | $30.39 | $104.85 |
| Average True Range (ATR) | 0.52 | 4.36 |
| MACD | -0.08 | -0.29 |
| Stochastic Oscillator | 28.04 | 36.84 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.